Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04381143 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ASPIrin in Reducing Events in Dialysis ( ASPIRED )

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 14, 2026 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoingv14 Show 4 more changesShow less
    • Trial sites reduced: 139 → 127 locations
    • Enrollment target: estimated 9000 to confirmed 9082
    • Primary completion date: Sep 2026 to Sep 30, 2026
    • Study completion date: Dec 2026 to Dec 31, 2026
  2. Study sites: 135 to 139v13
  3. Study sites: 132 to 135v12
  4. Study sites: 110 to 132
    • Secondary endpoints: 10 to 11
    • Eligibility criteria expanded, about 4 words
    v11
  5. 2 versions Re-verified since Nov 5, 2024, no change to tracked fieldsv9-v10
Show 7 earlier versionsHide 7 earlier versions
  1. Primary completion date: Jul 2025 to Sep 2026v8 Show 6 more changesShow less
    • Study sites: 84 to 110
    • Study completion date: Jul 2026 to Dec 2026
    • Interventions: Aspirin 100 mg Oral Tablet (Drug) to Aspirin 100 mg Oral Tablet (Drug), Matching Placebo (Drug)
    • Eligibility criteria expanded, about 26 words
    • Secondary endpoints: details revised at 2 of 10 entries
    • Collaborator revised
  2. Re-verified, no change to tracked fieldsv7
  3. Study sites: 67 to 84v6
  4. Secondary endpoints: 9 to 10v5
  5. Study sites: 47 to 67v4
  6. Study sites: 35 to 47v3
  7. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Primary endpoint revised
    • Primary completion date: Apr 2025 to Jul 2025
    • Study completion date: Apr 2026 to Jul 2026
    • Start date changed from estimate of May 2020 to Jul 30, 2020
    • Secondary endpoints revised (9)
    • Site details revised at 35 of 35 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.
Trial Details
NCT Number NCT04381143
Lead Sponsor Guangdong Provincial People's Hospital
Collaborators: The George Institute
Conditions
(from sponsor)		 CKD (Chronic Kidney Disease) Stage 5D
Related terms Kidney Failure, Chronic, Renal Insufficiency, Chronic
Enrollment 9,082 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov